 Robert Enzenauer
Concepts (533)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Amblyopia | 7 | 2023 | 8 | 1.950 |
Why?
| | Ophthalmologic Surgical Procedures | 8 | 2019 | 55 | 1.650 |
Why?
| | Vision Screening | 4 | 2023 | 8 | 1.630 |
Why?
| | Retinopathy of Prematurity | 8 | 2021 | 111 | 1.370 |
Why?
| | Strabismus | 9 | 2017 | 26 | 1.340 |
Why?
| | Refractive Errors | 4 | 2023 | 13 | 1.290 |
Why?
| | Oculomotor Muscles | 11 | 2017 | 38 | 1.250 |
Why?
| | Cornea | 9 | 2021 | 102 | 1.230 |
Why?
| | Ophthalmology | 6 | 2021 | 75 | 0.910 |
Why?
| | Eye Injuries, Penetrating | 3 | 2013 | 16 | 0.830 |
Why?
| | Military Personnel | 8 | 2018 | 521 | 0.740 |
Why?
| | Military Medicine | 4 | 2016 | 92 | 0.740 |
Why?
| | Eye Injuries | 8 | 2016 | 42 | 0.730 |
Why?
| | Eye Foreign Bodies | 3 | 2014 | 23 | 0.710 |
Why?
| | Photography | 3 | 2010 | 88 | 0.690 |
Why?
| | Chemical Warfare Agents | 6 | 2021 | 119 | 0.660 |
Why?
| | Exotropia | 4 | 2006 | 5 | 0.640 |
Why?
| | Patient Simulation | 1 | 2019 | 29 | 0.630 |
Why?
| | Down Syndrome | 1 | 2023 | 335 | 0.620 |
Why?
| | Lighting | 2 | 2016 | 25 | 0.620 |
Why?
| | Tensile Strength | 2 | 2017 | 88 | 0.610 |
Why?
| | Amnion | 1 | 2017 | 24 | 0.590 |
Why?
| | Equipment Design | 1 | 2019 | 503 | 0.560 |
Why?
| | Teaching | 1 | 2019 | 209 | 0.550 |
Why?
| | Esotropia | 4 | 2006 | 6 | 0.540 |
Why?
| | Wound Healing | 3 | 2017 | 254 | 0.530 |
Why?
| | Diagnostic Techniques, Ophthalmological | 3 | 2016 | 35 | 0.530 |
Why?
| | Color Vision | 1 | 2016 | 2 | 0.520 |
Why?
| | Color | 1 | 2016 | 68 | 0.510 |
Why?
| | Neonatal Screening | 5 | 2021 | 151 | 0.480 |
Why?
| | Delivery of Health Care | 2 | 2013 | 828 | 0.470 |
Why?
| | Boxing | 5 | 1994 | 6 | 0.450 |
Why?
| | Humans | 112 | 2023 | 114043 | 0.450 |
Why?
| | Ophthalmic Solutions | 5 | 2017 | 66 | 0.440 |
Why?
| | Visual Acuity | 11 | 2013 | 272 | 0.440 |
Why?
| | Tissue Adhesions | 2 | 2017 | 26 | 0.440 |
Why?
| | Surgical Procedures, Operative | 1 | 2016 | 206 | 0.430 |
Why?
| | Retinoscopes | 1 | 2011 | 1 | 0.370 |
Why?
| | Rabbits | 8 | 2021 | 733 | 0.360 |
Why?
| | Insurance, Liability | 1 | 2010 | 6 | 0.360 |
Why?
| | Dacryocystitis | 1 | 2010 | 3 | 0.360 |
Why?
| | Mucocele | 1 | 2010 | 11 | 0.350 |
Why?
| | Infant, Newborn | 26 | 2021 | 5038 | 0.350 |
Why?
| | Nonprescription Drugs | 2 | 2003 | 68 | 0.350 |
Why?
| | Pupil Disorders | 1 | 2010 | 5 | 0.340 |
Why?
| | Corneal Injuries | 2 | 2021 | 33 | 0.340 |
Why?
| | Mustard Gas | 3 | 2021 | 117 | 0.340 |
Why?
| | Reimbursement Mechanisms | 1 | 2010 | 76 | 0.340 |
Why?
| | Surveys and Questionnaires | 8 | 2021 | 4595 | 0.340 |
Why?
| | Conjunctival Diseases | 2 | 2017 | 17 | 0.330 |
Why?
| | Sensitivity and Specificity | 6 | 2023 | 1690 | 0.330 |
Why?
| | Vitrectomy | 2 | 2007 | 57 | 0.330 |
Why?
| | Warfare | 3 | 2018 | 74 | 0.320 |
Why?
| | Decompression, Surgical | 3 | 2019 | 92 | 0.310 |
Why?
| | Mechlorethamine | 3 | 2019 | 63 | 0.310 |
Why?
| | Corneal Neovascularization | 3 | 2017 | 12 | 0.300 |
Why?
| | Developmental Disabilities | 1 | 2011 | 236 | 0.300 |
Why?
| | Vitreous Detachment | 1 | 2007 | 5 | 0.300 |
Why?
| | Endophthalmitis | 3 | 1999 | 25 | 0.290 |
Why?
| | Optic Neuropathy, Ischemic | 1 | 2007 | 30 | 0.290 |
Why?
| | Optic Disk | 1 | 2007 | 38 | 0.280 |
Why?
| | Infant | 25 | 2017 | 7943 | 0.280 |
Why?
| | Birth Weight | 5 | 2017 | 439 | 0.280 |
Why?
| | Vitreous Body | 1 | 2007 | 101 | 0.280 |
Why?
| | Arsenicals | 2 | 2017 | 23 | 0.270 |
Why?
| | Circumcision, Male | 5 | 1987 | 14 | 0.270 |
Why?
| | Photorefractive Keratectomy | 1 | 2006 | 13 | 0.260 |
Why?
| | Orbit | 3 | 2013 | 52 | 0.260 |
Why?
| | Horner Syndrome | 1 | 2006 | 2 | 0.260 |
Why?
| | Choristoma | 1 | 2006 | 21 | 0.260 |
Why?
| | Corneal Transplantation | 2 | 2005 | 10 | 0.250 |
Why?
| | Indans | 1 | 2005 | 9 | 0.250 |
Why?
| | Predictive Value of Tests | 3 | 2023 | 1791 | 0.250 |
Why?
| | Nootropic Agents | 1 | 2005 | 27 | 0.250 |
Why?
| | Glaucoma, Angle-Closure | 1 | 2005 | 16 | 0.250 |
Why?
| | Neck | 1 | 2006 | 85 | 0.250 |
Why?
| | Hypergammaglobulinemia | 2 | 1999 | 9 | 0.250 |
Why?
| | Retinal Hemorrhage | 5 | 2013 | 18 | 0.240 |
Why?
| | Keratomileusis, Laser In Situ | 1 | 2005 | 16 | 0.240 |
Why?
| | Child | 17 | 2023 | 18400 | 0.240 |
Why?
| | Multiple Sclerosis | 1 | 2010 | 372 | 0.240 |
Why?
| | Thymus Gland | 1 | 2006 | 296 | 0.240 |
Why?
| | Ocular Motility Disorders | 2 | 2003 | 25 | 0.230 |
Why?
| | Vitamin A Deficiency | 1 | 2004 | 27 | 0.230 |
Why?
| | Mathematical Computing | 1 | 2004 | 12 | 0.230 |
Why?
| | Contact Lenses, Hydrophilic | 2 | 1997 | 5 | 0.230 |
Why?
| | Piperidines | 1 | 2005 | 159 | 0.230 |
Why?
| | Orbital Fractures | 1 | 2004 | 8 | 0.230 |
Why?
| | Vision, Ocular | 2 | 2016 | 30 | 0.220 |
Why?
| | Male | 54 | 2020 | 55396 | 0.220 |
Why?
| | Corneal Diseases | 2 | 2015 | 32 | 0.220 |
Why?
| | Dry Eye Syndromes | 1 | 2003 | 28 | 0.210 |
Why?
| | Female | 46 | 2017 | 59325 | 0.210 |
Why?
| | Reproducibility of Results | 3 | 2023 | 2764 | 0.210 |
Why?
| | Diplopia | 1 | 2003 | 15 | 0.210 |
Why?
| | Suture Techniques | 3 | 1999 | 115 | 0.210 |
Why?
| | Drug Costs | 1 | 2003 | 92 | 0.210 |
Why?
| | Hospitalization | 3 | 2010 | 1762 | 0.210 |
Why?
| | Child, Preschool | 17 | 2020 | 9114 | 0.200 |
Why?
| | Eyelids | 3 | 2013 | 27 | 0.200 |
Why?
| | Risk Factors | 8 | 2023 | 8614 | 0.200 |
Why?
| | Astigmatism | 2 | 2011 | 10 | 0.200 |
Why?
| | Lupus Erythematosus, Systemic | 2 | 2003 | 220 | 0.200 |
Why?
| | Physical Examination | 1 | 2023 | 221 | 0.200 |
Why?
| | Blepharoptosis | 1 | 2002 | 6 | 0.200 |
Why?
| | Disabled Children | 1 | 2003 | 69 | 0.200 |
Why?
| | Granuloma, Foreign-Body | 1 | 2002 | 10 | 0.200 |
Why?
| | Oculomotor Nerve Diseases | 1 | 2002 | 9 | 0.200 |
Why?
| | Abducens Nerve Diseases | 1 | 2002 | 10 | 0.200 |
Why?
| | Myopia | 2 | 2011 | 36 | 0.190 |
Why?
| | Tissue Donors | 2 | 2005 | 314 | 0.190 |
Why?
| | Epithelium, Corneal | 3 | 2017 | 35 | 0.190 |
Why?
| | Leadership | 1 | 2004 | 291 | 0.190 |
Why?
| | Vigabatrin | 1 | 2021 | 18 | 0.180 |
Why?
| | Aniridia | 1 | 2020 | 5 | 0.180 |
Why?
| | Immunoglobulin G | 2 | 1999 | 766 | 0.180 |
Why?
| | PAX6 Transcription Factor | 1 | 2020 | 17 | 0.180 |
Why?
| | Socioeconomic Factors | 3 | 2021 | 1080 | 0.180 |
Why?
| | Retinal Diseases | 5 | 1994 | 76 | 0.180 |
Why?
| | Prospective Studies | 7 | 2019 | 6195 | 0.180 |
Why?
| | Codon, Nonsense | 1 | 2020 | 37 | 0.180 |
Why?
| | Arthritis | 3 | 2017 | 109 | 0.180 |
Why?
| | Disease Models, Animal | 3 | 2019 | 3498 | 0.180 |
Why?
| | Eye Proteins | 1 | 2020 | 70 | 0.180 |
Why?
| | Cyclooxygenase 2 | 5 | 2021 | 164 | 0.170 |
Why?
| | United States | 13 | 2021 | 12137 | 0.170 |
Why?
| | Drug Residues | 1 | 1999 | 5 | 0.170 |
Why?
| | Scleral Buckling | 1 | 1999 | 18 | 0.170 |
Why?
| | Wilms Tumor | 1 | 2020 | 67 | 0.170 |
Why?
| | Corneal Stroma | 2 | 2017 | 15 | 0.170 |
Why?
| | Eye Infections, Bacterial | 1 | 1999 | 24 | 0.170 |
Why?
| | Adolescent | 16 | 2016 | 17800 | 0.170 |
Why?
| | Sclera | 1 | 1999 | 35 | 0.170 |
Why?
| | Organ Preservation Solutions | 1 | 1999 | 37 | 0.160 |
Why?
| | Functional Laterality | 2 | 2010 | 196 | 0.160 |
Why?
| | Intraocular Pressure | 5 | 2013 | 275 | 0.160 |
Why?
| | Anticonvulsants | 1 | 2021 | 178 | 0.160 |
Why?
| | Lacrimal Apparatus | 1 | 2019 | 7 | 0.160 |
Why?
| | Organ Preservation | 1 | 1999 | 64 | 0.160 |
Why?
| | Immunoglobulin lambda-Chains | 1 | 1999 | 6 | 0.160 |
Why?
| | Paraproteinemias | 1 | 1999 | 4 | 0.160 |
Why?
| | Adult | 21 | 2018 | 30375 | 0.160 |
Why?
| | Retinal Vein Occlusion | 1 | 1999 | 13 | 0.160 |
Why?
| | Staphylococcal Infections | 3 | 2011 | 340 | 0.160 |
Why?
| | Pneumococcal Infections | 1 | 1999 | 91 | 0.160 |
Why?
| | Face | 1 | 2020 | 163 | 0.160 |
Why?
| | Vision Tests | 1 | 2018 | 15 | 0.150 |
Why?
| | Contrast Sensitivity | 1 | 2018 | 12 | 0.150 |
Why?
| | Color Perception | 1 | 2018 | 21 | 0.150 |
Why?
| | Retrospective Studies | 15 | 2021 | 12521 | 0.150 |
Why?
| | Matrix Metalloproteinase 9 | 4 | 2021 | 118 | 0.150 |
Why?
| | Athletic Injuries | 3 | 1989 | 456 | 0.150 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 1999 | 70 | 0.150 |
Why?
| | Retrobulbar Hemorrhage | 2 | 2009 | 3 | 0.150 |
Why?
| | Naphazoline | 1 | 1997 | 1 | 0.150 |
Why?
| | Pheniramine | 1 | 1997 | 1 | 0.150 |
Why?
| | Nasal Decongestants | 1 | 1997 | 8 | 0.150 |
Why?
| | Conjunctivitis, Allergic | 1 | 1997 | 3 | 0.150 |
Why?
| | Nerve Agents | 1 | 2017 | 4 | 0.150 |
Why?
| | Mydriasis | 1 | 1997 | 8 | 0.150 |
Why?
| | Histamine H1 Antagonists | 1 | 1997 | 28 | 0.150 |
Why?
| | Atropine | 1 | 2017 | 25 | 0.150 |
Why?
| | Conjunctiva | 1 | 2017 | 50 | 0.140 |
Why?
| | Farber Lipogranulomatosis | 1 | 2017 | 4 | 0.140 |
Why?
| | Meningitis | 3 | 1983 | 74 | 0.140 |
Why?
| | Synovitis | 1 | 2017 | 24 | 0.140 |
Why?
| | Antimetabolites | 1 | 1997 | 21 | 0.140 |
Why?
| | Health Personnel | 2 | 2000 | 569 | 0.140 |
Why?
| | Educational Measurement | 1 | 2019 | 235 | 0.140 |
Why?
| | Quality Indicators, Health Care | 1 | 1999 | 285 | 0.140 |
Why?
| | Kidney Neoplasms | 1 | 2020 | 324 | 0.140 |
Why?
| | Imaging, Three-Dimensional | 1 | 2020 | 511 | 0.140 |
Why?
| | Cicatrix | 1 | 1997 | 49 | 0.140 |
Why?
| | Infant, Low Birth Weight | 1 | 2017 | 124 | 0.130 |
Why?
| | Swine | 1 | 2019 | 687 | 0.130 |
Why?
| | Orbital Neoplasms | 2 | 1993 | 19 | 0.130 |
Why?
| | False Positive Reactions | 2 | 2011 | 109 | 0.130 |
Why?
| | Fluorouracil | 1 | 1997 | 152 | 0.130 |
Why?
| | Infant, Newborn, Diseases | 3 | 1982 | 104 | 0.130 |
Why?
| | Uveitis | 1 | 2017 | 115 | 0.130 |
Why?
| | Magnetic Resonance Imaging | 6 | 2010 | 3039 | 0.130 |
Why?
| | Weight Gain | 2 | 2016 | 453 | 0.130 |
Why?
| | Antidotes | 1 | 2017 | 135 | 0.130 |
Why?
| | Animals | 9 | 2021 | 31565 | 0.130 |
Why?
| | Visual Fields | 3 | 2007 | 77 | 0.130 |
Why?
| | Public Health | 1 | 2000 | 433 | 0.130 |
Why?
| | Algorithms | 3 | 2017 | 1469 | 0.130 |
Why?
| | Fibrosis | 1 | 2017 | 452 | 0.120 |
Why?
| | Convergence, Ocular | 1 | 1995 | 6 | 0.120 |
Why?
| | Ethanol | 1 | 1999 | 534 | 0.120 |
Why?
| | Household Products | 1 | 2015 | 6 | 0.120 |
Why?
| | Afghanistan | 2 | 2007 | 108 | 0.120 |
Why?
| | Eye Burns | 1 | 2015 | 11 | 0.120 |
Why?
| | Treatment Outcome | 9 | 2011 | 9049 | 0.120 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2017 | 286 | 0.120 |
Why?
| | Quality of Health Care | 1 | 1999 | 572 | 0.120 |
Why?
| | Burns, Chemical | 1 | 2015 | 25 | 0.120 |
Why?
| | Keratitis | 2 | 2017 | 11 | 0.120 |
Why?
| | Interleukin-8 | 3 | 2021 | 229 | 0.120 |
Why?
| | Gestational Age | 5 | 2017 | 761 | 0.120 |
Why?
| | Slit Lamp | 1 | 2014 | 2 | 0.110 |
Why?
| | Hyphema | 1 | 2013 | 4 | 0.110 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2019 | 496 | 0.110 |
Why?
| | Biomarkers | 2 | 2021 | 3397 | 0.110 |
Why?
| | DNA Damage | 1 | 2016 | 351 | 0.110 |
Why?
| | Keratotomy, Radial | 1 | 1993 | 9 | 0.110 |
Why?
| | Lymphangioma | 1 | 1993 | 7 | 0.110 |
Why?
| | Blindness | 2 | 2009 | 36 | 0.110 |
Why?
| | Health Care Surveys | 2 | 2010 | 541 | 0.110 |
Why?
| | Scleral Diseases | 1 | 1992 | 1 | 0.110 |
Why?
| | Staphylococcus | 2 | 2011 | 69 | 0.100 |
Why?
| | Child Abuse | 3 | 2013 | 456 | 0.100 |
Why?
| | Abducens Nerve | 1 | 1992 | 3 | 0.100 |
Why?
| | Dura Mater | 1 | 1992 | 27 | 0.100 |
Why?
| | Eye Infections, Fungal | 1 | 1992 | 6 | 0.100 |
Why?
| | Drug Therapy, Combination | 4 | 2012 | 949 | 0.100 |
Why?
| | Skull Neoplasms | 1 | 1992 | 22 | 0.100 |
Why?
| | Anesthetics, Dissociative | 1 | 2012 | 28 | 0.100 |
Why?
| | Follow-Up Studies | 8 | 2011 | 4392 | 0.100 |
Why?
| | Craniocerebral Trauma | 3 | 2013 | 133 | 0.100 |
Why?
| | Glucocorticoids | 4 | 2017 | 526 | 0.100 |
Why?
| | Opportunistic Infections | 1 | 1992 | 43 | 0.100 |
Why?
| | Cranial Nerve Diseases | 1 | 1992 | 42 | 0.100 |
Why?
| | Doxycycline | 1 | 2012 | 54 | 0.100 |
Why?
| | Double-Blind Method | 2 | 2011 | 1656 | 0.100 |
Why?
| | Aged | 13 | 2016 | 18969 | 0.100 |
Why?
| | Hospitals, Military | 3 | 2007 | 32 | 0.100 |
Why?
| | Paralysis | 1 | 1992 | 66 | 0.100 |
Why?
| | Foreign Bodies | 1 | 2013 | 93 | 0.100 |
Why?
| | Vision, Binocular | 4 | 2005 | 15 | 0.090 |
Why?
| | Ketamine | 1 | 2012 | 92 | 0.090 |
Why?
| | Middle Aged | 12 | 2016 | 26605 | 0.090 |
Why?
| | Anisometropia | 1 | 2011 | 1 | 0.090 |
Why?
| | Hyperopia | 1 | 2011 | 3 | 0.090 |
Why?
| | Anti-Bacterial Agents | 4 | 2012 | 1471 | 0.090 |
Why?
| | Orbital Cellulitis | 1 | 2011 | 14 | 0.090 |
Why?
| | Silymarin | 1 | 2012 | 194 | 0.090 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2013 | 222 | 0.090 |
Why?
| | Facial Pain | 1 | 1990 | 11 | 0.090 |
Why?
| | Gingivitis | 1 | 1990 | 12 | 0.090 |
Why?
| | Postoperative Complications | 2 | 2017 | 2122 | 0.090 |
Why?
| | Retina | 3 | 2021 | 263 | 0.090 |
Why?
| | Dexamethasone | 1 | 2012 | 316 | 0.090 |
Why?
| | Light | 1 | 2013 | 336 | 0.090 |
Why?
| | Malpractice | 1 | 2010 | 37 | 0.090 |
Why?
| | Corneal Keratocytes | 2 | 2021 | 7 | 0.090 |
Why?
| | Fluorescein Angiography | 4 | 1999 | 104 | 0.080 |
Why?
| | Fat Emulsions, Intravenous | 1 | 1990 | 27 | 0.080 |
Why?
| | Immunoglobulin Light Chains | 1 | 1990 | 36 | 0.080 |
Why?
| | Incidental Findings | 1 | 2010 | 70 | 0.080 |
Why?
| | Retinal Vessels | 1 | 1990 | 50 | 0.080 |
Why?
| | Drug Industry | 1 | 1990 | 103 | 0.080 |
Why?
| | Aerospace Medicine | 3 | 2014 | 19 | 0.080 |
Why?
| | Nocardia Infections | 1 | 1989 | 7 | 0.080 |
Why?
| | Corneal Ulcer | 2 | 2004 | 14 | 0.080 |
Why?
| | Enteral Nutrition | 1 | 1990 | 157 | 0.080 |
Why?
| | Urinary Tract Infections | 2 | 1987 | 131 | 0.080 |
Why?
| | Blood Vessels | 2 | 2021 | 179 | 0.070 |
Why?
| | Color Perception Tests | 1 | 2007 | 3 | 0.070 |
Why?
| | Prevalence | 2 | 2013 | 2247 | 0.070 |
Why?
| | Autopsy | 1 | 2007 | 83 | 0.070 |
Why?
| | Health Services Research | 1 | 2010 | 373 | 0.070 |
Why?
| | Sudden Infant Death | 1 | 2007 | 24 | 0.070 |
Why?
| | Eye Movements | 3 | 2005 | 51 | 0.070 |
Why?
| | Fundus Oculi | 6 | 1994 | 40 | 0.070 |
Why?
| | Accidents, Traffic | 2 | 2013 | 169 | 0.070 |
Why?
| | Time Factors | 4 | 2017 | 6077 | 0.070 |
Why?
| | Tomography, Optical Coherence | 1 | 2007 | 130 | 0.070 |
Why?
| | Shaken Baby Syndrome | 1 | 2006 | 5 | 0.070 |
Why?
| | Nasolacrimal Duct | 1 | 2006 | 5 | 0.070 |
Why?
| | Lacrimal Duct Obstruction | 1 | 2006 | 4 | 0.070 |
Why?
| | Chromosome Inversion | 1 | 1986 | 17 | 0.070 |
Why?
| | Chromosomes, Human, Pair 15 | 1 | 1986 | 53 | 0.070 |
Why?
| | Videotape Recording | 1 | 1986 | 30 | 0.070 |
Why?
| | Lasers, Excimer | 1 | 2006 | 21 | 0.070 |
Why?
| | Infant, Very Low Birth Weight | 2 | 2017 | 66 | 0.070 |
Why?
| | Colorado | 4 | 2017 | 4090 | 0.070 |
Why?
| | Refraction, Ocular | 1 | 2006 | 30 | 0.070 |
Why?
| | Adenocarcinoma | 1 | 1992 | 787 | 0.070 |
Why?
| | Optic Nerve Diseases | 1 | 2006 | 31 | 0.070 |
Why?
| | Health Surveys | 2 | 2006 | 441 | 0.070 |
Why?
| | Chromosome Aberrations | 1 | 1986 | 134 | 0.060 |
Why?
| | Diagnosis, Differential | 2 | 2006 | 1331 | 0.060 |
Why?
| | Parenteral Nutrition, Total | 1 | 1985 | 27 | 0.060 |
Why?
| | Cell Survival | 2 | 2021 | 1014 | 0.060 |
Why?
| | Skin Diseases, Infectious | 1 | 1985 | 15 | 0.060 |
Why?
| | Reoperation | 3 | 1999 | 513 | 0.060 |
Why?
| | Quality Control | 1 | 2006 | 143 | 0.060 |
Why?
| | Prostatic Neoplasms | 1 | 1992 | 913 | 0.060 |
Why?
| | Smoking Prevention | 1 | 1986 | 157 | 0.060 |
Why?
| | Refractive Surgical Procedures | 1 | 2005 | 5 | 0.060 |
Why?
| | Intellectual Disability | 1 | 1986 | 127 | 0.060 |
Why?
| | Pyoderma | 1 | 1984 | 2 | 0.060 |
Why?
| | Ethics | 1 | 2004 | 5 | 0.060 |
Why?
| | Night Blindness | 1 | 2004 | 6 | 0.060 |
Why?
| | Myxoma | 1 | 1984 | 11 | 0.060 |
Why?
| | Xerophthalmia | 1 | 2004 | 7 | 0.060 |
Why?
| | Mitral Valve Stenosis | 1 | 1984 | 22 | 0.060 |
Why?
| | Organizational Objectives | 1 | 2004 | 66 | 0.060 |
Why?
| | Data Interpretation, Statistical | 1 | 2006 | 318 | 0.060 |
Why?
| | Heart Neoplasms | 1 | 1984 | 49 | 0.060 |
Why?
| | Chloramphenicol | 1 | 1983 | 6 | 0.060 |
Why?
| | Ampicillin | 1 | 1983 | 13 | 0.060 |
Why?
| | Esophageal Diseases | 1 | 1984 | 24 | 0.060 |
Why?
| | Theophylline | 1 | 1984 | 60 | 0.060 |
Why?
| | Disability Evaluation | 1 | 2005 | 271 | 0.060 |
Why?
| | Tobacco Smoke Pollution | 1 | 1986 | 217 | 0.050 |
Why?
| | Young Adult | 2 | 2016 | 10444 | 0.050 |
Why?
| | Cross Infection | 1 | 1985 | 194 | 0.050 |
Why?
| | Preservatives, Pharmaceutical | 1 | 2003 | 24 | 0.050 |
Why?
| | Immunohistochemistry | 2 | 2019 | 1624 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 2 | 2010 | 1175 | 0.050 |
Why?
| | Syndrome | 3 | 2020 | 330 | 0.050 |
Why?
| | Counseling | 1 | 1986 | 342 | 0.050 |
Why?
| | Drug Packaging | 1 | 2003 | 42 | 0.050 |
Why?
| | Corneal Opacity | 2 | 2016 | 6 | 0.050 |
Why?
| | Femoral Fractures | 2 | 1992 | 64 | 0.050 |
Why?
| | Pleura | 1 | 1983 | 18 | 0.050 |
Why?
| | Intermittent Positive-Pressure Ventilation | 1 | 1983 | 9 | 0.050 |
Why?
| | Drug Combinations | 2 | 1997 | 286 | 0.050 |
Why?
| | Cohort Studies | 3 | 2017 | 4883 | 0.050 |
Why?
| | Illinois | 2 | 2000 | 37 | 0.050 |
Why?
| | Cholestasis | 1 | 1985 | 225 | 0.050 |
Why?
| | Diagnostic Imaging | 1 | 2005 | 278 | 0.050 |
Why?
| | Methylprednisolone | 1 | 2003 | 80 | 0.050 |
Why?
| | Citrobacter | 1 | 1982 | 1 | 0.050 |
Why?
| | Positive-Pressure Respiration | 1 | 1983 | 68 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2003 | 214 | 0.050 |
Why?
| | Incidence | 3 | 2013 | 2314 | 0.050 |
Why?
| | Abducens Nerve Injury | 1 | 2002 | 1 | 0.050 |
Why?
| | Oculomotor Nerve Injuries | 1 | 2002 | 1 | 0.050 |
Why?
| | Radiography, Thoracic | 1 | 1983 | 150 | 0.050 |
Why?
| | Enterobacteriaceae Infections | 1 | 1982 | 33 | 0.050 |
Why?
| | Parents | 2 | 2006 | 1181 | 0.050 |
Why?
| | Pectoralis Muscles | 1 | 1981 | 13 | 0.050 |
Why?
| | Hydrocephalus | 1 | 1982 | 83 | 0.050 |
Why?
| | Infant, Premature | 2 | 2017 | 478 | 0.050 |
Why?
| | Electroretinography | 1 | 2021 | 40 | 0.050 |
Why?
| | Patient Education as Topic | 2 | 2003 | 666 | 0.050 |
Why?
| | Tibial Fractures | 1 | 1982 | 67 | 0.050 |
Why?
| | Severity of Illness Index | 2 | 2005 | 2537 | 0.050 |
Why?
| | Physician-Patient Relations | 1 | 2005 | 459 | 0.040 |
Why?
| | Appendicitis | 1 | 1982 | 112 | 0.040 |
Why?
| | Alzheimer Disease | 1 | 2005 | 442 | 0.040 |
Why?
| | Cataract | 1 | 2003 | 184 | 0.040 |
Why?
| | Acute Disease | 2 | 2019 | 907 | 0.040 |
Why?
| | Eosinophilia | 1 | 1982 | 186 | 0.040 |
Why?
| | Administration, Oral | 2 | 2017 | 725 | 0.040 |
Why?
| | Colon | 1 | 1982 | 232 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 4 | 1999 | 2272 | 0.040 |
Why?
| | Therapeutic Irrigation | 1 | 1999 | 65 | 0.040 |
Why?
| | Risk | 3 | 1989 | 810 | 0.040 |
Why?
| | Leukemia | 1 | 1981 | 208 | 0.040 |
Why?
| | Chlorambucil | 1 | 1999 | 8 | 0.040 |
Why?
| | Vitreous Hemorrhage | 1 | 1999 | 6 | 0.040 |
Why?
| | Retinal Detachment | 1 | 1999 | 52 | 0.040 |
Why?
| | Physical Therapy Modalities | 1 | 1982 | 265 | 0.040 |
Why?
| | Sodium Chloride | 1 | 1999 | 133 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2003 | 641 | 0.040 |
Why?
| | Quality of Life | 2 | 2006 | 2343 | 0.040 |
Why?
| | Streptococcus pneumoniae | 1 | 1999 | 133 | 0.040 |
Why?
| | Lens, Crystalline | 1 | 1999 | 90 | 0.040 |
Why?
| | Risk Assessment | 2 | 2017 | 2958 | 0.040 |
Why?
| | Brain | 1 | 2010 | 2355 | 0.040 |
Why?
| | Corneal Pachymetry | 1 | 2017 | 14 | 0.040 |
Why?
| | Prednisone | 1 | 1999 | 229 | 0.040 |
Why?
| | Blister | 1 | 2017 | 43 | 0.040 |
Why?
| | Administration, Intranasal | 1 | 2017 | 75 | 0.040 |
Why?
| | Fluorometholone | 1 | 2017 | 4 | 0.040 |
Why?
| | Biological Availability | 1 | 2017 | 119 | 0.040 |
Why?
| | Bone Marrow | 1 | 1999 | 243 | 0.040 |
Why?
| | Optometry | 1 | 1997 | 2 | 0.040 |
Why?
| | Task Performance and Analysis | 1 | 2018 | 160 | 0.040 |
Why?
| | Nod2 Signaling Adaptor Protein | 1 | 2017 | 30 | 0.030 |
Why?
| | Intraoperative Period | 1 | 1997 | 51 | 0.030 |
Why?
| | Laser Coagulation | 1 | 2017 | 53 | 0.030 |
Why?
| | Administration, Topical | 1 | 1997 | 137 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2004 | 1381 | 0.030 |
Why?
| | Prognosis | 3 | 2020 | 3315 | 0.030 |
Why?
| | Infant, Extremely Low Birth Weight | 1 | 2016 | 15 | 0.030 |
Why?
| | Battered Child Syndrome | 2 | 1992 | 6 | 0.030 |
Why?
| | Rupture | 1 | 2016 | 96 | 0.030 |
Why?
| | Organ Culture Techniques | 1 | 2016 | 140 | 0.030 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2016 | 157 | 0.030 |
Why?
| | Pilot Projects | 1 | 2000 | 1360 | 0.030 |
Why?
| | Sarcoidosis | 1 | 2017 | 133 | 0.030 |
Why?
| | Apoptosis | 2 | 2016 | 2349 | 0.030 |
Why?
| | Eye | 1 | 2016 | 97 | 0.030 |
Why?
| | Uveomeningoencephalitic Syndrome | 1 | 1995 | 6 | 0.030 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2017 | 176 | 0.030 |
Why?
| | Surgical Wound Dehiscence | 1 | 1994 | 19 | 0.030 |
Why?
| | Mass Screening | 1 | 2021 | 979 | 0.030 |
Why?
| | Scotoma | 1 | 1994 | 4 | 0.030 |
Why?
| | Agenesis of Corpus Callosum | 1 | 1994 | 12 | 0.030 |
Why?
| | Choroid Diseases | 1 | 1994 | 9 | 0.030 |
Why?
| | Choroiditis | 1 | 1994 | 6 | 0.030 |
Why?
| | Surgery, Plastic | 1 | 1994 | 24 | 0.030 |
Why?
| | Accidents, Home | 1 | 2013 | 28 | 0.030 |
Why?
| | Ophthalmoplegia | 1 | 1993 | 8 | 0.030 |
Why?
| | Facial Paralysis | 1 | 1993 | 17 | 0.030 |
Why?
| | Nerve Fibers, Myelinated | 1 | 1993 | 41 | 0.030 |
Why?
| | Cataract Extraction | 1 | 1994 | 75 | 0.030 |
Why?
| | Contraindications | 1 | 1993 | 84 | 0.030 |
Why?
| | Tamoxifen | 1 | 1994 | 190 | 0.030 |
Why?
| | Iris | 1 | 1993 | 19 | 0.030 |
Why?
| | Blotting, Western | 1 | 2016 | 1143 | 0.030 |
Why?
| | Dark Adaptation | 1 | 2013 | 13 | 0.030 |
Why?
| | Aviation | 1 | 2013 | 9 | 0.030 |
Why?
| | Fungemia | 1 | 1992 | 3 | 0.030 |
Why?
| | Cranial Fossa, Posterior | 1 | 1992 | 16 | 0.030 |
Why?
| | Ocular Physiological Phenomena | 1 | 1992 | 11 | 0.030 |
Why?
| | Aspergillosis | 1 | 1992 | 23 | 0.030 |
Why?
| | Candidiasis | 1 | 1992 | 51 | 0.030 |
Why?
| | Eye Diseases | 1 | 1993 | 74 | 0.030 |
Why?
| | Models, Statistical | 1 | 2016 | 595 | 0.030 |
Why?
| | Vision Disorders | 1 | 1993 | 127 | 0.020 |
Why?
| | Irritants | 1 | 2012 | 41 | 0.020 |
Why?
| | Emergencies | 2 | 2009 | 143 | 0.020 |
Why?
| | Mycoses | 1 | 1992 | 66 | 0.020 |
Why?
| | Heparin | 1 | 2013 | 225 | 0.020 |
Why?
| | Aged, 80 and over | 4 | 2005 | 6306 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2016 | 1836 | 0.020 |
Why?
| | Vision Disparity | 1 | 1991 | 2 | 0.020 |
Why?
| | Sex Factors | 3 | 1987 | 1706 | 0.020 |
Why?
| | Radiography | 3 | 1985 | 803 | 0.020 |
Why?
| | Thrombocytopenia | 1 | 2013 | 177 | 0.020 |
Why?
| | Emergency Medical Services | 1 | 2018 | 581 | 0.020 |
Why?
| | Crohn Disease | 1 | 1994 | 196 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2012 | 1003 | 0.020 |
Why?
| | Lung | 1 | 1983 | 3521 | 0.020 |
Why?
| | Coloboma | 1 | 1990 | 4 | 0.020 |
Why?
| | Retinal Perforations | 1 | 1990 | 12 | 0.020 |
Why?
| | Circadian Rhythm | 1 | 1993 | 356 | 0.020 |
Why?
| | Pigment Epithelium of Eye | 1 | 1990 | 34 | 0.020 |
Why?
| | Safflower Oil | 1 | 1990 | 4 | 0.020 |
Why?
| | Light Coagulation | 1 | 1990 | 7 | 0.020 |
Why?
| | Soybean Oil | 1 | 1990 | 12 | 0.020 |
Why?
| | Sacroiliac Joint | 2 | 1994 | 29 | 0.020 |
Why?
| | Emulsions | 1 | 1990 | 42 | 0.020 |
Why?
| | HEPES | 1 | 1989 | 2 | 0.020 |
Why?
| | Chondroitin | 1 | 1989 | 5 | 0.020 |
Why?
| | Tissue Preservation | 1 | 1989 | 11 | 0.020 |
Why?
| | Propionibacterium acnes | 1 | 1989 | 8 | 0.020 |
Why?
| | Graft Rejection | 1 | 1992 | 511 | 0.020 |
Why?
| | Indians, North American | 1 | 1995 | 564 | 0.020 |
Why?
| | Gentamicins | 1 | 1989 | 42 | 0.020 |
Why?
| | Chondroitin Sulfates | 1 | 1989 | 33 | 0.020 |
Why?
| | Nocardia asteroides | 1 | 1989 | 1 | 0.020 |
Why?
| | Sulfacetamide | 1 | 1989 | 1 | 0.020 |
Why?
| | Trimethoprim | 1 | 1989 | 6 | 0.020 |
Why?
| | Sulfamethoxazole | 1 | 1989 | 6 | 0.020 |
Why?
| | Anticoagulants | 1 | 2013 | 547 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 445 | 0.020 |
Why?
| | Models, Biological | 1 | 2016 | 1611 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2016 | 2173 | 0.020 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1989 | 38 | 0.020 |
Why?
| | Antioxidants | 1 | 2012 | 529 | 0.020 |
Why?
| | Phospholipids | 1 | 1990 | 194 | 0.020 |
Why?
| | Gastrointestinal Diseases | 1 | 1990 | 182 | 0.020 |
Why?
| | Forensic Medicine | 1 | 2007 | 16 | 0.020 |
Why?
| | Brain Injuries | 1 | 1992 | 459 | 0.020 |
Why?
| | Recurrence | 1 | 1990 | 925 | 0.020 |
Why?
| | Piperazines | 1 | 1989 | 310 | 0.020 |
Why?
| | Mutation | 1 | 2017 | 3338 | 0.020 |
Why?
| | Orbit Evisceration | 1 | 2006 | 1 | 0.020 |
Why?
| | Forensic Pathology | 1 | 2006 | 6 | 0.020 |
Why?
| | Dacryocystorhinostomy | 1 | 2006 | 9 | 0.020 |
Why?
| | Hawaii | 1 | 1986 | 38 | 0.020 |
Why?
| | Sickness Impact Profile | 1 | 2006 | 50 | 0.020 |
Why?
| | Chromosome Disorders | 1 | 1986 | 35 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 1986 | 167 | 0.020 |
Why?
| | Wounds, Nonpenetrating | 1 | 2009 | 249 | 0.020 |
Why?
| | Klebsiella pneumoniae | 1 | 1985 | 41 | 0.020 |
Why?
| | Informed Consent | 1 | 1986 | 158 | 0.020 |
Why?
| | Length of Stay | 1 | 1989 | 957 | 0.010 |
Why?
| | Arthritis, Rheumatoid | 1 | 1992 | 1002 | 0.010 |
Why?
| | Arthritis, Infectious | 1 | 1985 | 49 | 0.010 |
Why?
| | Hirschsprung Disease | 1 | 1985 | 90 | 0.010 |
Why?
| | Tablets | 1 | 1984 | 36 | 0.010 |
Why?
| | Abdominal Muscles | 1 | 1983 | 3 | 0.010 |
Why?
| | Penicillin Resistance | 1 | 1983 | 8 | 0.010 |
Why?
| | Ulcer | 1 | 1984 | 28 | 0.010 |
Why?
| | Meningitis, Haemophilus | 1 | 1983 | 6 | 0.010 |
Why?
| | Mitral Valve | 1 | 1984 | 94 | 0.010 |
Why?
| | Haemophilus influenzae | 1 | 1983 | 48 | 0.010 |
Why?
| | Hernia, Umbilical | 1 | 1983 | 17 | 0.010 |
Why?
| | Feces | 1 | 1985 | 372 | 0.010 |
Why?
| | Kidney | 1 | 1990 | 1182 | 0.010 |
Why?
| | Attitude of Health Personnel | 2 | 1987 | 970 | 0.010 |
Why?
| | Health Services Misuse | 1 | 1983 | 36 | 0.010 |
Why?
| | Angiostrongylus | 1 | 1982 | 1 | 0.010 |
Why?
| | Age Distribution | 1 | 2003 | 341 | 0.010 |
Why?
| | Nematode Infections | 1 | 1982 | 4 | 0.010 |
Why?
| | Infant, Premature, Diseases | 1 | 1983 | 88 | 0.010 |
Why?
| | Rupture, Spontaneous | 1 | 1982 | 16 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2005 | 1218 | 0.010 |
Why?
| | Age Factors | 1 | 1989 | 2885 | 0.010 |
Why?
| | Contracture | 1 | 1982 | 23 | 0.010 |
Why?
| | Enema | 1 | 1982 | 37 | 0.010 |
Why?
| | Leukemia, Lymphoid | 1 | 1981 | 27 | 0.010 |
Why?
| | Glucagon | 1 | 1982 | 92 | 0.010 |
Why?
| | Elbow Joint | 1 | 1982 | 59 | 0.010 |
Why?
| | Skin | 1 | 1985 | 653 | 0.010 |
Why?
| | Regression Analysis | 1 | 2003 | 945 | 0.010 |
Why?
| | Hip Joint | 1 | 1982 | 124 | 0.010 |
Why?
| | Contrast Media | 1 | 1982 | 347 | 0.010 |
Why?
| | Knee Joint | 1 | 1982 | 322 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2006 | 4402 | 0.010 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 1981 | 533 | 0.010 |
Why?
| | Spasm | 1 | 1994 | 19 | 0.010 |
Why?
| | Spondylitis | 1 | 1994 | 1 | 0.010 |
Why?
| | Sulfasalazine | 1 | 1994 | 21 | 0.010 |
Why?
| | Tenosynovitis | 1 | 1994 | 11 | 0.010 |
Why?
| | Crystallization | 1 | 1994 | 136 | 0.010 |
Why?
| | Middle East | 1 | 1993 | 10 | 0.010 |
Why?
| | Cadaver | 1 | 1994 | 298 | 0.010 |
Why?
| | Accommodation, Ocular | 1 | 1993 | 10 | 0.010 |
Why?
| | Rib Fractures | 1 | 1992 | 25 | 0.010 |
Why?
| | Posture | 1 | 1993 | 152 | 0.010 |
Why?
| | Muscles | 1 | 1993 | 320 | 0.010 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 1994 | 296 | 0.010 |
Why?
| | Reference Values | 1 | 1992 | 739 | 0.010 |
Why?
| | Postoperative Care | 1 | 1991 | 223 | 0.010 |
Why?
| | Drug Contamination | 1 | 1989 | 51 | 0.010 |
Why?
| | Culture Media | 1 | 1989 | 155 | 0.010 |
Why?
| | Macular Degeneration | 1 | 1990 | 152 | 0.000 |
Why?
| | Suppuration | 1 | 1985 | 8 | 0.000 |
Why?
| | Technetium Tc 99m Medronate | 1 | 1985 | 4 | 0.000 |
Why?
| | Gallium Radioisotopes | 1 | 1985 | 12 | 0.000 |
Why?
| | Radionuclide Imaging | 1 | 1985 | 115 | 0.000 |
Why?
| | Breast Neoplasms | 1 | 1994 | 1846 | 0.000 |
Why?
| | Aging | 1 | 1990 | 1611 | 0.000 |
Why?
| | Pediatrics | 1 | 1987 | 982 | 0.000 |
Why?
|
|
Enzenauer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|